Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03511521 · ClinicalTrials.gov registry record · Phase 4
Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia
A Phase 4 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT03511521: Clinical Trial Phase 4 study, sponsored by Northwestern University.
NCT03511521 is a Phase 4 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03511521, a Phase 4 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
Glucocorticoids are known to cause an increase in insulin resistance, leading to hyperglycemia, in both diabetic and non-diabetic patients. In both the inpatient and outpatient setting, steroids are used for their anti-inflammatory property to treat a variety of conditions. There is a paucity of information regarding the best way to treat steroid-induced hyperglycemia. In this study we will compare (1) the addition of NPH insulin, an intermediate-acting insulin, given at the time of steroid administration to the patient's standard basal/bolus insulin to (2) modification of the standard basal-bolus insulin regimen which will consist primarily increasing the prandial doses at lunch and supper in order to determine which regimen is superior for glycemic control.
Primary Outcome
mean of 4 glucose levels per day (premeal and bedtime) for each group for first 3 days after intervention
Interventions
- DRUG NPH Insulin
- DRUG Insulin Aspart
- DRUG glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-03-27 |
| Est. Completion | 2019-08-15 |
| Phase | Phase 4 |
Why NCT03511521 stopped before completion
NCT03511521 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which NPH Insulin is the first listed.
NCT03511521 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03511521 about?
NCT03511521 is a clinical study titled "Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia". Glucocorticoids are known to cause an increase in insulin resistance, leading to hyperglycemia, in both diabetic and non-diabetic patients. In both the inpatient and outpatient setting, steroids are used for their anti-inflammatory property to treat a variety of conditions. There is a paucity of inf...
What is the current status of trial NCT03511521?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2018-03-27. Estimated completion is 2019-08-15.
What interventions are being tested in trial NCT03511521?
The interventions under investigation include: NPH Insulin (DRUG), Insulin Aspart (DRUG), glargine (DRUG).
Who is sponsoring clinical trial NCT03511521?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03511521's enrollment target sits among peer trials
3 1995th of 2000 higher than 3 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI